Bin Wu

Company: Cytodigm, Inc.

Job title: Founder & Chief Executive Officer

Seminars:

Exploring Treatment Engineering Approaches to Overcome Off-Target Toxicity 2:15 pm

Analyzing the antibody approach to targeting and discussing immunogenicity and toxicity produced by antibody conjugation Investigating alternative strategies to enhance targeting and improve safety profiles without antibody conjugation Presenting Cytodigm’s novel approach to target extrahepatic tissues and cell while reducing off-target toxicityRead more

day: Day One

Roundtable Discussion: Overcoming Treatment Uptake by the Liver to Enhance Delivery Efficiency & Prevent Hepatotoxicity 2:45 pm

Exploring surface binders as a strategy to de-target the liver and enhance precision Reimagining vehicle design to de-target the liver, improving treatment uptake and delivery efficiency Developing strategies to detoxify the liver to prevent hepatotoxicity and improve patient outcomesRead more

day: Day One